31 July 2023
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
CMC
Gene Therapy
GMP
Point of Care
Regulatory & Standards
Scaling Up
Strategy
At Advanced Therapies Week 2023, Carol Houts, Chief Strategy Officer at Germfree, sat down with a few invited guests at the Germfree booth to discuss the challenges and opportunities associated with delivering cell therapies in a distributed and point-of-care manufacturing models. Watch the full series, below.
This series consists of 5 panels, including:
- Regulatory Challenges – Distributed and Point-of-Care Manufacturing Models. “Do we Have a Regulatory Framework?” With Heath Coats, Dark Horse Consulting
- Regulatory Challenges – Product Quality (CMC) Challenges and Opportunities with David Lewandowski, Azenta Life Sciences
- 5 Minutes with Germfree, with Kevin Kyle, Germfree
- Distributed and Point-of-Care Manufacturing – Pharmaceutical QMS Essentials Digital Systems with Lynn Fischer, Title21 Health Solutions and Najib Rehman, ATMPS
- Building Infrastructure and Capacity with Edwin Stone, Cellular Origins and Krisha Patel, Assurea, LLC
Panel 1: Regulatory Challenges – Distributed and Point-of-Care Manufacturing Models. “Do we Have a Regulatory Framework?”
This first panel features insights from Heath Coats, Senior Practice Expert at Dark Horse Consulting.
Panel 2: Regulatory Challenges – Product Quality (CMC) Challenges and Opportunities
This panel features insights from David Lewandowski, Director, Business Development at Azenta Life Sciences.
Panel 3: 5 Minutes with Germfree
This 5 minute interlude features insights from Kevin Kyle Chief Executive Officer at Germfree.
Panel 4: Distributed and Point-of-Care Manufacturing – Pharmaceutical QMS Essentials Digital Systems
This panel features insights from Lynn Fischer, Chief Executive Officer, Title21 Health Solutions and Najib Rehman, Digital Automation Lead at ATMPS.
Panel 5: Building Infrastructure and Capacity
This panel feature insights from Edwin Stone, Chief Executive Officer at Cellular Origins and Krisha Patel, Co-Founder of Assurea, LLC.
These panels were produced in partnership with Germfree.
More like this
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment
Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023
Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux
Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023
The Cell & Gene Therapy Manufacturing Capacity Map
The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023
